Response Scientific Inc. (RSI) has developed a patented new prescription medical food called Receptorex ( a patented prescription medical food for people with type 1 and type 2 diabetes) candidate that sensitizes the body's insulin receptors to perform more efficiently, thereby requiring less insulin to maintain healthy blood glucose levels.

The discovery, code-named INS2 branded Receptorex, has demonstrated the ability to dramatically reduce the amount of insulin required by insulin-dependent people with Type 2 Diabetes by as much as 50 percent. This efficacy presents itself in a matter of a few days, increasing its effectiveness steadily over one to two weeks to reach peak levels. "This is a promising day for anyone living with diabetes; the results of this discovery could change the lives of millions of people around the world," said Gregg Webster, RSI president and CEO. Our company is dedicated to the healthcare of people with insulin-sensitivity issues including diabetes, Polycystic Ovarian Syndrome (PCOS), and Alzheimer's disease."